Dr. Olszanski on Patient Selection for Cemiplimab Treatment in CSCC

Описание: Anthony J. Olszanski, MD, RPh, vice chair, Department of Hematology/Oncology, director, Early Drug Development Phase 1 Program, Fox Chase Cancer Center, discusses the treatment selection process for use of cemiplimab (Libtayo) in patients with cutaneous squamous cell carcinoma (CSCC).

For patients with CSCC who are referred to the medical oncologist, this means the surgeon has indicated that they are not candidates for surgical resection. In this case, a multidisciplinary team including the surgeon, radiation oncologist, medical oncologist, and a dermatologist will need to review the case to determine the best treatment plan, says Olszanski.

For those that are not candidates for surgery nor radiation, Olszanski says that cemiplimab can play a vital role. This PD-L1 inhibitor has been well tolerated, demonstrated high response rates, and can be easier to administer than chemotherapy.